Kidney Cancer

Latest News

April 7th 2022

Peter Humphrey, MD, PhD, Talks Multidisciplinary Aspects of Oncology Research

At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Peter Humphrey, MD, PhD, spoke about how the conference catered to the multidisciplinary audience, and what he learned from that.

Latest Videos

Renal Cell Carcinoma: Practical Advice for Patients, Caregivers, and Physicians

Metastatic Renal Cell Carcinoma: Communicating Treatment Options With Patients

Clinical Scenario 1: Renal Cell Carcinoma Diagnosis and Staging

The Evolving Landscape of Renal Cell Carcinoma Management

Support Networks for Patients With Renal Cell Carcinoma

Managing Adverse Events While on Treatment for Renal Cell Carcinoma

Treatment Decision Making in RCC: Patient and Caregiver Perspectives

Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.

AI-Based Model May Guide Decision-Making in Kidney Cancer Based on CT, EGFR

Treatment for RCC: Educating Patients on Followup and Adverse Events

Renal Cell Carcinoma: Expert Perspectives on Treatment Selection

CME Content

Video

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | Iowa

Sapna Patel, MD; Rakesh Bagai, MD

Video

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | New York

Yana G. Najjar, MD; Deepa Jagtap, MD

Video

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | Minnesota

Yana G. Najjar, MD; Anand Patel, MD

In-Person Event

20th Annual New York Lung Cancers Symposium®

November 15, 2025

Video

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | Texas

Yana G. Najjar, MD; Kara Schenk, MD

Video

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | Washington

Yana G. Najjar, MD; Albert Dekker, MD

Video

PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?

Richard S. Finn, MD; Anthony B. El-Khoueiry, MD; Pierre Gholam, MD; Lipika Goyal, MD

Multimedia

Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board

Andre H. Goy, MD; Monique Hartley-Brown, MD, MMSc (Guest Co-Chair); Chiara Battelli, MD, PhD; Marios Giannakis, MD, PhD; Shail Maingi, MD; Aparna Parikh, MD

Multimedia

Navigating Low-Grade Serous Ovarian Cancer – Enhancing Diagnosis, Sequencing Therapy, and Contextualizing Novel Advances

Kathleen N. Moore, MD, MS, FASCO; Susana Banerjee, MBBS, MA, FRCP, PhD; David M. O’Malley, MD; Ritu Salani, MD, MBA

Multimedia

Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS, FASCO; David M. O’Malley, MD

Multimedia

Advances In™: Taking R/R B-Cell ALL Management to the Next Level With New CAR T Approval

Daniel J. DeAngelo, MD, PhD; Claire Roddie, MD, PhD

Multimedia

Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care

Kathleen N. Moore, MD, MS, FASCO; Ritu Salani, MD, MBA

Video

Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies

Mark G. Kris, MD; Justin Gainor, MD; Isabel Preeshagul, DO, MBS; Helena A. Yu, MD

Multimedia

Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials

Kathleen N. Moore, MD, MS, FASCO; Prof Susana Banerjee, MBBS, MA, FRCP, PhD

Video

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | Louisiana

Jacob Sands, MD; Uday Dandamudi, MD

Video

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | Colorado

Sapna Patel, MD; Jyothi Dodlapati, MD

Video

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | Montana and Wyoming

Jacob Sands, MD; Brian Vicuna, MD

In-Person + Virtual Event

Annual Hematology Meeting: Preceding the 67th ASH Annual Meeting and Exposition

December 5, 2025

In-Person + Virtual Event

Breast Cancer Symposia in San Antonio

December 8-11, 2025

Multimedia

Burst CME™: How is the Newly Approved CAR T-Cell Therapy Impacting R/R B-Cell ALL Management?

Jae H. Park, MD

Virtual Event

Evolving Strategies and Emerging Agents in PTCL: Subtypes, Mutations, and Modern Therapies

December 19, 2025

Multimedia

Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care

Tiffany A. Traina, MD, FASCO; Demetria Smith-Graziani, MD, MPH

Video

Epithelioid Sarcoma: Applying Clinical Updates to Real Patient Cases

Mark Agulnik, MD; Shaina A. Rozell, MD, MPH

Video

Collaborating Across the Continuum®: Identifying and Treating Epithelioid Sarcoma

Mark Agulnik, MD; Mrinal M. Gounder, MD; Jacqueline M. Kraveka, DO; Lee M. Zuckerman, MD

Multimedia

Mastering Epithelioid Sarcoma: Enhancing Diagnostic Precision and Tailoring Treatment Strategies

Mark Agulnik, MD; Mrinal M. Gounder, MD; Jacqueline M. Kraveka, DO; Daniel Lefler, MD; Shaina A. Rozell, MD, MPH; Lee M. Zuckerman, MD

Case-based Simulation

Clinical Showcase™: Selecting the Best Next Steps for a Patient with Epithelioid Sarcoma

Mark Agulnik, MD; Daniel Lefler, MD

In-Person Event

Inaugural Brain & Spine Metastases Conference: Evolving Practice and Emerging Therapies

January 22, 2026

In-Person Event

2nd Annual Hawaii Cancer Conference

January 24-25, 2026

Video

Medical Crossfire®: Bridging Evidence to Practice in AML…Updates on FLT3, IDH1/2, Maintenance, Combos, and Clinical Trials

Naval G. Daver, MD; Jessica Altman, MD; Amir T. Fathi, MD; Gail J. Roboz, MD; Joshua Zeidner, MD

Video

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Estelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MD

Video

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Anne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MD

Video

Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers

Zev A. Wainberg, MD; Manish A. Shah, MD, FASCO; Syma Iqbal, MD

In-Person Event

19th Annual New York GU Cancers Congress™

March 13-14, 2026

Video

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

Jennifer R. Brown, MD, PhD; Alexey V. Danilov, MD, PhD; Matthew S. Davids, MD, MMSc

Video

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Stephen V. Liu, MD; Michelle Afkhami, MD; Ignacio I. Wistuba, MD; Helena Yu, MD

In-Person Event

11th Annual School of Gastrointestinal Oncology® (SOGO®)

April 11, 2026

Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Ghassan Abou-Alfa, MD, MBA

Multimedia

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Hope S. Rugo, MD, FASCO; Neil M. Iyengar, MD; Komal Jhaveri, MD, FACP

Multimedia

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Video

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Shubham Pant, MD, MBBS

Video

Proactive Adverse Event Management for HER2+ BTC Treatments

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Rachna T. Shroff, MD, MS, FASCO

Multimedia

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

Yana G. Najjar, MD; Douglas B. Johnson, MD, MSCI; Rahul A. Sheth, MD, FSIR

Video

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Cindy Neunert, MD, MSCS; Hanny Al-Samkari, MD; Joseph Shatzel, MD, MCR

Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Balazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MD

Video

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Jonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Video

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

John H. Strickler, MD; Stacey A. Cohen, MD; Aparna Parikh, MD; Kanwal P.S. Raghav, MBBS, MD

Video

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Rami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MD

$Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma$

Video

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Video

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Rebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhD

Video

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Gail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHS

Video

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Eileen M. O’Reilly, MD; E. Gabriela Chiorean, MD, FASCO; Michael J. Pishvaian, MD, PhD; Brian Wolpin, MD, MPH

Video

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen J. Bagley, MD, MSCE; Angela Waanders, MD, MPH, MS

Video

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

Multimedia

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Multimedia

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc

Multimedia

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD

Multimedia

Establishing the Rationale for ADC and ICI Combinations in TNBC

Virginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCO

Multimedia

Breaking Down the Rationale for Targeting TROP2 in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Audio

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Hossein Borghaei, DO, MS

Video

Cross-Disease Integration of Immunotherapy Innovations

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Video

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Video

Optimizing Treatment for Biliary Tract Cancers

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Multimedia

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCO

Video

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Ana C. Garrido-Castro, MD; Pedram Razavi, MD, PhD

Audio

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhD

Multimedia

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

Audio

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhD

Multimedia

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Video

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Sandip Patel, MD, FASCO; Myung-Ju Ahn, MD; Giannis Mountzios, MD, MSc, PhD; Zofia Piotrowska, MD, MHS

Video

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Tina Cascone, MD, PhD; Christina Baik, MD, MPH; David Planchard, MD, PhD

Multimedia

Community Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary Team

Yana G. Najjar, MD; Sapna Patel, MD

Video

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Video

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

More News

The Influence of Risk Category Stratification Algorithms on CLEAR Trial Data

ByThomas E. Hutson, DO, PharmD,Scott S. Tykodi, MD, PhD

March 31st 2022

Thomas Hutson, DO, PharmD, and Scott Tykodi, MD, PhD, discuss their takeaways from the CLEAR trial and how risk category stratification affected the study.

A Physician’s Take on the CLEAR Trial Data

ByBrian Shimkus, MD,Tom Powles, MBBS, MRCP, MD

March 31st 2022

Brian Shimkus, MD, shares his opinion of data on lenvatinib and pembrolizumab from the CLEAR trial.

The Role of Genetic Mutations in Prognosis and Decision-Making

ByChung-Han Lee, MD, PhD, Memorial Sloan Kettering Cancer Center

March 30th 2022

Chung-Han Lee, MD, PhD discusses how genetic mutations inform patient prognosis and decision-making for patients with kidney cancer.

Prognostic Value of Biomarkers in RCC

ByRobert S. Alter, MD

March 30th 2022

Robert Alter, MD opines on the current prognostic value of biomarkers for RCC and the need for additional data in the field.

Biomarker Testing: Methodologies, Sample Types, and Emerging Data

ByMehmet Asim Bilen, MD

March 30th 2022

Mehmet Asim Bilen, MD weighs in on various biomarker testing methodologies, sample considerations, and emerging data on novel biomarkers.

Biomarker Testing in RCC: Current Approaches

ByDavid Aggen, MD, PhD

March 30th 2022

David Aggen, MD, PhD reviews how he currently approaches biomarker testing in patients with RCC.

Metastatic RCC: Prognosis and Recent Advances in Care

ByMehmet Asim Bilen, MD

March 30th 2022

Mehmet Asim Bilen, MD comments on the prognosis of patients with metastatic RCC and how recent advances have improved outcomes.

Risk Models and Prognostic Factors

ByRobert S. Alter, MD

March 30th 2022

Robert Alter, MD comments on the use of prognostic models for determining risk status and informing treatment options in patients with RCC.

Laurence Albigès, MD, PhD, discusses how immunotherapy combinations have affected the treatment landscape for previously untreated advanced or metastatic renal cell carcinoma.

Laurence Albigès, MD, PhD, on the Potential Impact of Immunotherapy-Based Combinations in Advanced RCC

ByLaurence Albigès, MD, PhD

March 29th 2022

Laurence Albigès, MD, PhD, discusses how immunotherapy combinations have affected the treatment landscape for previously untreated advanced or metastatic renal cell carcinoma.

Laurence Albigès, MD, PhD, spotlighted 2-year follow-up data from the phase 3 CheckMate 9ER trial, which looked at nivolumab and cabozantinib in patients with previously untreated advanced or metastatic renal cell carcinoma.

Laurence Albigès, MD, PhD, on Key Findings With Nivolumab/Cabozantinib in Advanced RCC

ByLaurence Albigès, MD, PhD

March 27th 2022

Laurence Albigès, MD, PhD, spotlighted 2-year follow-up data from the phase 3 CheckMate 9ER trial, which looked at nivolumab and cabozantinib in patients with previously untreated advanced or metastatic renal cell carcinoma.

Laurence Albigès, MD, PhD, speaks to how patients with treatment-naïve advanced or metastatic renal cell carcinoma can benefit from treatment with nivolumab and ipilimumab.

Laurence Albigès, MD, PhD, on the Benefit of Nivolumab Plus Ipilimumab for Advanced RCC

ByLaurence Albigès, MD, PhD

March 26th 2022

Laurence Albigès, MD, PhD, speaks to how patients with treatment-naïve advanced or metastatic renal cell carcinoma can benefit from treatment with nivolumab and ipilimumab.

Laurence Albigès, MD, PhD, shares updated key findings from the phase 3 CheckMate 214 trial.

Laurence Albigès, MD, PhD, on Key Findings From CheckMate 214 of Nivolumab Plus Ipilimumab in Advanced RCC

ByLaurence Albigès, MD, PhD

March 25th 2022

Laurence Albigès, MD, PhD, shares updated key findings from the phase 3 CheckMate 214 trial.

Gennady Bratslavsky, MD, Discusses Future of Surgery in RCC

ByGennady Bratslavsky, MD

March 24th 2022

Gennady Bratslavsky, MD, spoke about the evolving field of surgery for renal cell carcinoma at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies.

The Changing Treatment Landscape and the Role of Surgery in RCC

ByAriana Pelosci

March 24th 2022

Gennady Bratslavsky, MD, spoke about the evolution for treatments in renal cell carcinoma and how surgery may play a role.

Laurence Albigès, MD, PhD, speaks to the patient population included in the phase 3 CheckMate 214 trial, assessing nivolumab plus ipilimumab in patients with treatment-naïve advanced or metastatic renal cell carcinoma.

Laurence Albigès, MD, PhD, Describes Population With Advanced RCC Receiving Nivolumab Plus Ipilimumab in the CheckMate-214 Trial

ByLaurence Albigès, MD, PhD

March 22nd 2022

Laurence Albigès, MD, PhD, speaks to the patient population included in the phase 3 CheckMate 214 trial, assessing nivolumab plus ipilimumab in patients with treatment-naïve advanced or metastatic renal cell carcinoma.

Discovering Treatment Biomarkers Remains an Important Goal in RCC

ByAudrey Sternberg

March 21st 2022

For Kidney Cancer Awareness Month, CancerNetwork® spoke with Daniel M. Geynisman, MD, about how emerging data in the treatment of renal cell carcinoma stand to further impact the standard of care.

Impressions of Data and Results from the CLEAR Trial

ByMehmet Asim Bilen, MD,Marie Carlo, MD,Robert J. Motzer, MD,Moshe Ornstein, MD, MA,Brian I. Rini, MD,Rana R. McKay, MD,Tom Powles, MBBS, MRCP, MD

March 18th 2022

Oncologists give their initial impressions about the results of a clinical trial studying doublet combination therapies for advanced renal cell carcinoma.

Background: Lenvatinib + Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

ByMehmet Asim Bilen, MD,Marie Carlo, MD,Robert J. Motzer, MD,Moshe Ornstein, MD, MA,Brian I. Rini, MD,Rana R. McKay, MD,Tom Powles, MBBS, MRCP, MD

March 18th 2022

Robert J. Motzer, MD, presents data examined in the article, “Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.”

Activity in Ongoing Trials Suggest New Agents Are on the Horizon for RCC

ByAriana Pelosci

March 17th 2022

For Kidney Cancer Awareness Month, Toni K. Choueiri, MD, spoke with CancerNetwork® about ongoing trials clinicians need to be aware of.

Combining Surgical and Therapeutic Treatment Options in Evolving Field of RCC

ByAriana Pelosci

March 16th 2022

Gennady Bratslavsky, MD, discusses the ever-changing field of treatment options for renal cell carcinoma at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, hosted by Physicians’ Education Resource®, LLC.

Choueiri Discusses Updated KEYNOTE-564 Results of Adjuvant Pembrolizumab in RCC

ByToni K. Choueiri, MD

March 16th 2022

At 2022 ASCO GU, Toni K. Choueiri, MD, explained the data seen in the updated results from the KEYNOTE-564 trial for patients with renal cell carcinoma.

In recognition of Kidney Cancer Awareness Month, CancerNetwork® spoke with Laurence Albigès, MD, PhD, about immunotherapy combination trials for renal cell carcinoma that read out at the 2022 Genitourinary Cancers Symposium.

Examining Frontline Immune Checkpoint Inhibitor Combinations in Advanced RCC With Laurence Albigès, MD, PhD

ByHayley Virgil

March 15th 2022

In recognition of Kidney Cancer Awareness Month, CancerNetwork® spoke with Laurence Albigès, MD, PhD, about immunotherapy combination trials for renal cell carcinoma that read out at the 2022 Genitourinary Cancers Symposium.

As Treatment Options Abound, Clinicians Rely on Risk Stratification for Frontline RCC Management

ByAudrey Sternberg

March 15th 2022

Primo Nery Lara, Jr., MD, talks treatment of metastatic renal cell carcinoma in the first-line setting at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, hosted by Physicians’ Education Resource®, LLC.

Daniel M. Geynisman, MD, on Optimal Therapy Selection in RCC

ByDaniel M. Geynisman, MD

March 11th 2022

At 2022 ASCO GU, Daniel M. Geynisman, MD, spoke with CancerNetwork® about his strategy for treating renal cell carcinoma across lines of therapy.

RCC Paradigm Continues Moving Forward With New Combination Regimens on the Horizon

ByAriana Pelosci

March 10th 2022

For Kidney Cancer Awareness Month, CancerNetwork® spoke with Chung-Han Lee, MD, PhD, about research in renal cell carcinoma that has the greatest potential to impact the standard of care.